dalfampridine(redirected from Fampyra)
Unknown. May increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.
Tablets (extended release): 10 mg
Indications and dosages
➣ To improve walking in patients with multiple sclerosis
Adults: 10 mg P.O. q 12 hours
• Mild renal impairment
• History of seizures
• Moderate or severe renal impairment
Use cautiously in:
• mild renal impairment
• pregnant or breastfeeding patients
• children younger than age 18 (safety and efficacy not established).
• Check creatinine clearance before starting drug.
• Administer with or without food.
CNS: insomnia, dizziness, headache, asthenia, balance disorder, paresthesia, seizures
EENT: nasopharyngitis, pharyngolaryngeal pain
GI: nausea, constipation, dyspepsia
GU: urinary tract infection
Musculoskeletal: back pain
Other: multiple sclerosis relapse
Discontinue drug if seizure occurs.
• Monitor renal function tests regularly (especially creatinine clearance).
• Instruct patient to take drug with or without food.
• Instruct patient to swallow tablet whole and not to break, crush, chew, or dissolve it.
Advise patient to discontinue drug and immediately report to prescriber if seizures occur.
• Instruct patient to promptly report urinary tract problems.
• As appropriate, review all other significant and life-threatening adverse reactions.
ClassificationTherapeutic: anti multiple sclerosis agents
Pharmacologic: potassium channel blockers
Time/action profile (improvement in walking speed)
|PO||unk||3–4 hr||24 hr|
Adverse Reactions/Side Effects
Central nervous system
- seizures (life-threatening)
Ear, Eye, Nose, Throat
- pharyngolaryngeal pain
- urinary tract infection
- back pain
- balance disorder
- multiple sclerosis relapse
- anaphylaxis (life-threatening)
Drug-Drug interactionNone noted.
- Assess walking speed in patients with multiple sclerosis prior to and periodically during therapy.
- Monitor for seizures during therapy, risk increases with increased dose. If seizure occurs, discontinue therapy.
- Monitor for signs and symptoms of anaphylaxis (dyspnea, wheezing, urticaria, angioedema of the throat or tongue) during therapy.
- Lab Test Considerations: Monitor creatinine clearance prior to and at least yearly during therapy; renal impairment may require dose reduction or discontinuation.
Potential Nursing DiagnosesImpaired walking (Indications)
- Administer tablets twice daily approximately 12 hr apart without regard to food. Administer tablets whole; do not break, crush, chew, or dissolve.
- Instruct patient to take dalfampridine as directed, with approximately 12 hrs between tablets. If a dose is missed, omit and take next scheduled dose on time; do not double doses. May increase risk of seizures. Advise patient to read Medication Guide prior to beginning therapy and with each Rx refill; new information may be available.
- Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
- If a seizure or signs or symptoms of anaphylaxis occur, advise patient to notify health care professional immediately, to discontinue dalfampridine, and to report the event to Acorda (manufacturer) at 1-800-367-5109.
- Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.
- Improved walking and increased walking speed in patients with multiple sclerosis.